Overview
Compare with ASSEMBLY BIOSCIENCES, INC., OMEROS CORP or Viridian Therapeutics, Inc.\DE, or pick any stock.
- TickerBCYC on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersCambridge1
- Websitewww.bicycletherapeutics.com
- Legal formpublic limited company1
- Incorporated inUnited Kingdom5
- Business addressBlocks A & B, Portway Building, Granta Park, Great Abington, Cambridge, X0 Cb21 6Gs5
- Filer categoryNon-accelerated filer, Smaller reporting company5
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-340.4%Operating margin4
-301.7%Net margin4
105.8%Revenue growth, 20254
-35.9%Return on equity4
-$252.0MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$240.3M
- Income tax0¢$152.0K
Out of $72.6M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Collaboration revenue | $72.6M | $35.3M | $27.0M |
| Research and development | $240.3M | $173.0M | $156.5M |
| General and administrative | $79.4M | $72.2M | $60.4M |
| Total operating expenses | $319.7M | $245.1M | $216.9M |
| Loss from operations | -$247.1M | -$209.9M | -$189.9M |
| Interest and other income | $28.5M | $34.3M | $14.0M |
| Interest expense | -$206.0K | -$1.7M | -$3.3M |
| Loss on extinguishment of debt | -$954.0K | ||
| Gain on extinguishment of research and development funding liability | $4.5M | ||
| Total other income, net | $28.3M | $36.1M | $10.7M |
| Net loss before income tax provision | -$218.8M | -$173.8M | -$179.2M |
| Provision for (benefit from) income taxes | $152.0K | -$4.8M | $1.5M |
| Net loss | -$219.0M | -$169.0M | -$180.7M |
| Net loss per share, basic (in dollars per share) | -$3.16 | -$2.90 | -$5.08 |
| Net loss per share, diluted (in dollars per share) | -$3.16 | -$2.90 | -$5.08 |
| Weighted average ordinary shares outstanding, basic (in shares) | 69.3M shares | 58.2M shares | 35.6M shares |
| Weighted average ordinary shares outstanding, diluted (in shares) | 69.3M shares | 58.2M shares | 35.6M shares |
| Foreign currency translation adjustment | -$3.6M | $1.4M | -$1.7M |
| Total comprehensive loss | -$222.6M | -$167.6M | -$182.4M |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $628.1M | $879.5M | $526.4M |
| Prepaid expenses and other current assets | $19.2M | $13.4M | |
| Research and development incentives receivable | $35.6M | $35.7M | |
| Total current assets | $682.9M | $928.6M | |
| Property and equipment, net | $6.0M | $9.5M | |
| Operating lease right-of-use assets | $15.9M | $7.7M | |
| Other assets | $12.8M | $11.1M | |
| Total assets | $717.6M | $956.9M | |
| Accounts payable | $9.7M | $15.8M | |
| Accrued expenses and other current liabilities | $44.4M | $41.2M | |
| Deferred revenue, current portion | $3.0M | $10.2M | |
| Total current liabilities | $57.0M | $67.2M | |
| Operating lease liabilities, net of current portion | $14.1M | $4.0M | |
| Deferred revenue, net of current portion | $35.5M | $91.5M | |
| Other longterm liabilities | $1.0M | $1.1M | |
| Total liabilities | $107.6M | $163.8M | |
| Ordinary shares, including non-voting ordinary shares, 0.01 nominal value; 159,685,229 and 155,876,645 shares authorized at December 31, 2025 and December 31, 2024, respectively; 69,367,896 and 69,061,418 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $894.0K | $890.0K | |
| Additional paid-in capital | $1.5B | $1.5B | |
| Accumulated other comprehensive (loss) income | -$3.5M | $119.0K | |
| Accumulated deficit | -$899.8M | -$680.8M | |
| Total shareholders' equity | $610.0M | $793.1M | $370.9M |
| Total liabilities and shareholders' equity | $717.6M | $956.9M | |
| Ordinary shares, nominal value | 0.01 GBP | 0.01 GBP | |
| Ordinary shares, shares authorized | 159.7M shares | 155.9M shares | |
| Ordinary shares, shares issued | 69.4M shares | 69.1M shares | |
| Ordinary shares, shares outstanding | 69.4M shares | 69.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$219.0M | -$169.0M | -$180.7M |
| Share-based compensation expense | $39.5M | $38.1M | $32.5M |
| Depreciation and amortization | $6.4M | $7.2M | $6.5M |
| Non-cash interest | $211.0K | $383.0K | |
| Loss on extinguishment of debt | $954.0K | ||
| Gain on extinguishment of research and development funding liability | -$4.5M | ||
| Deferred income tax (benefit) provision | -$850.0K | -$5.2M | $3.3M |
| Other non-cash charges | $1.0M | $661.0K | |
| Accounts receivable | $2.5M | ||
| Research and development incentives receivable | $2.9M | -$11.9M | -$3.7M |
| Prepaid expenses and other assets | -$5.8M | -$2.0M | -$2.1M |
| Operating lease rightofuse assets | $4.6M | $4.4M | $4.2M |
| Accounts payable | -$6.9M | $3.1M | $8.0M |
| Accrued expenses and other current liabilities | $4.1M | $9.7M | $2.4M |
| Operating lease liabilities | -$5.5M | -$4.9M | -$4.1M |
| Deferred revenue | -$69.2M | -$32.0M | $69.0M |
| Other long-term liabilities | $189.0K | $509.0K | |
| Net cash used in operating activities | -$249.7M | -$164.7M | -$60.6M |
| Purchases of property and equipment | -$2.4M | -$1.2M | -$2.9M |
| Net cash used in investing activities | -$2.4M | -$1.2M | -$2.9M |
| Repayment of debt | -$31.9M | ||
| Proceeds from the issuance of ADSs and non-voting ordinary shares, net of issuance costs | $544.1M | $249.3M | |
| Proceeds from the exercise of share options and settlement of restricted share units | $37.0K | $7.5M | $682.0K |
| Principal payments on finance lease obligations | -$168.0K | -$42.0K | |
| Net cash (used in) provided by financing activities | -$131.0K | $519.8M | $250.0M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $804.0K | -$694.0K | $1.3M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$251.4M | $353.1M | $187.8M |
| Cash paid for interest on debt | $1.4M | $2.8M | |
| Cash paid for interest on finance lease obligations | $78.0K | $23.0K | |
| Cash (received from) paid for income taxes | -$717.0K | $792.0K | $562.0K |
| Cash paid for amounts included in the measurement of operating lease liabilities | $6.0M | $5.8M | $5.6M |
| Changes in purchases of property and equipment in accounts payable and accrued expenses | -$4.0K | -$1.7M | |
| Non-cash impact to operating lease right-of-use assets and operating lease liabilities | $12.4M | $3.9M | |
| Property and equipment obtained under finance leases | $1.1M |
Compare Bicycle Therapeutics (United Kingdom) with another company
Former names
- BICYCLE THERAPEUTICS LtdDec 21, 2018 to May 24, 20195
Timeline
- 2009Founded Founded1
Recent filings
- Oct 7, 20264/A
- Oct 6, 20263/A
- Oct 6, 20264
- Oct 6, 20264
- Oct 6, 20264
- Oct 6, 20264
- Oct 6, 20264
- Oct 6, 20264
- Oct 2, 2026144
- Aug 20, 20268-K
- Aug 14, 2026SCHEDULE 13G/A
- Jul 30, 20268-K
- Jul 30, 202610-Q
- Jul 17, 20264
- Jul 17, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.bicycletherapeutics.com1
- WikidataQ104480022
- SEC EDGARCIK 1761612
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteBicycle Therapeutics (United Kingdom) logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15